Page 2 - Diabetes

India to make Ozempic-like drugs for diabetes, obesity under PLI by 2026

GLP-1RA works by activating GLP-1 receptors in the pancreas, which leads to enhanced insulin release and reduced glucagon release responses

Olympic athletes turn to diabetes tech in pursuit of winning medals

The Paris Olympics, which start on July 26, are an opportunity to showcase the technology - even though there is as yet no proof it can boost athletic performance

Can diabetes be cured? Chinese doctors claim breakthrough with cell therapy

A 59-year-old man with type 2 diabetes received an innovative cell transplant and has been insulin-free and off medication for 33 months, offering hope to other diabetes patients

Can diabetes be cured?

Not so sweet anymore: How India's relationship with sugar is turning sour

With rising incomes, education, and health awareness in India, especially in the big cities, droves of people are saying no to sugar

Asking for insulin daily: Kejriwal writes to Tihar superintendent

Delhi Chief Minister Arvind Kejriwal on Monday wrote to superintendent of Tihar jail where he is lodged since April 1, claiming he has been asking for insulin every day and that AIIMS doctors never said there was no reason to worry about his diabetic condition. His letter to the superintendent comes a day after the Tihar administration issued a statement stating they had arranged his video conference with senior specialists from AIIMS during which neither "the issue of insulin was raised by Kejriwal, nor was it suggested by the doctors". The chief minister alleged that the Tihar administration issued a "false and misleading" statement under "political pressure". There was no immediate reaction from Tihar jail authorities on Delhi chief minister's allegations. Delhi cabinet minister Atishi shared Kejriwal's letter on her X handle. The chief minister rejected the jail administration's claim that the issue of insulin was never raised by him in his consultations with the doctors. "Th

'Conspiracy to kill Kejriwal': AAP says he's being denied insulin in jail

'ED should be afraid of God for lying so much; AAP to hold protests in Delhi: Party leaders

Biocon partners Biomm SA to commercialise it's diabetes drug in Brazil

Biotechnology firm Biocon on Wednesday said it has tied up with Brazil-based Biomm SA for the commercialisation of its diabetes drug in the Latin American nation. Under the terms of the agreement, Biocon will undertake the development, manufacturing and supply of Semaglutide (gOzempic), and Biomm will be responsible for obtaining regulatory approval and commercialization in the Brazilian market. Biomm focuses on developing, manufacturing and commercialising complex biotech and biosimilar drug products at its production facility in Nova Lima. "Our partnership with Biomm marks another important step forward in our strategy to expand our global footprint beyond the US and Europe for Peptides," Biocon CEO and MD Siddharth Mittal said in a statement. This is also in line with the growth strategy of bringing to market a portfolio of complex, GLP-1 drug-device combination products, he added. "We are confident that our collaboration with Biomm will provide patients in Brazil, who are livi

Besides Covid-19, diabetes and renal disease reduce Indian lifespan

Covid-19 was the leading cause of death in India, as per the study. The age-standardised rate of deaths for both males and females was 156.8 per 100,000 population

Preventive online health checkups rise 50% in India: Simpl Checkout Scan

Lifestyle-based checkups including diabetes, vitamin deficiency and hair fall, apart from comprehensive full-body checkups, are the most preferred by Indians

Non-Covid deaths high in people with diabetes, women affected more: Study

Non-Covid-related deaths increased among people having diabetes because of pandemic-related disruptions, new research published in The Lancet Diabetes and Endocrinology journal has found. The global review of studies comparing pre-pandemic and during-pandemic data found that the complication of sight loss in people with diabetes also increased. The negative impacts were most pronounced for women, younger people and racial and ethnic minority groups, it found. The team of researchers, including those from the World Health Organization (WHO), looked at 138 studies - North America (39), Western Europe (39), Asia (17) and others from Eastern Europe, South America, Egypt, Australia and multiple regions - to examine the impacts of pandemic-related disruptions on the vulnerable diabetic population. The research findings pointed to the importance of ensuring that all people with diabetes, especially those from the less advantaged groups, had consistent access to diabetes medication and care

Glenmark cuts diabetes drug cost by 70% with first Indian biosimilar launch

Drug, marketed under the brand name Lirafit, is priced at approximately Rs 100 for a standard daily dose of 1.2 mg

Glenmark Pharmaceuticals launches antidiabetic drug 'Lirafit' in India

Glenmark Pharmaceuticals on Wednesday said it has launched a biosimilar of the popular antidiabetic drug, Liraglutide in India. The drug is being marketed under the brand name Lirafit following the approval from the Drug Controller General of India (DCGI), the company said in a statement. It is priced at around Rs 100 for a standard dose of 1.2mg (per day) and will lower the cost of therapy by approximately 70 per cent, the company claimed. Lirafit will be available only under prescription. "Clinical trials have shown that it helps improve glycemic control in adult type 2 diabetes mellitus patients along with atherosclerotic cardiovascular diseases (ASCVD) and obesity," Glenmark Pharmaceuticals President and Business Head India Formulations, Alok Malik said. Liraglutide has also proven to have a positive impact on cardiac and renal safety outcomes among patients in clinical trials, making it an effective choice of treatment for patients with type 2 diabetes mellitus, he added. "W

50% surge in diabetes in individuals under 40 yrs of age, say experts

India is often dubbed as the diabetic capital of the world where nearly 11 per cent of the population is grappling with the disease

Karwa Chauth: All you need to know about fasting tips for diabetic women

Karwa Chauth is a delightful and sacred Hindu Celebration. In India, particularly in Northern parts of India, women fast from sunrise to moonrise for the well-being and long life of their spouses

Prefer deductible to co-pay in senior citizen health insurance cover

Last week Tata AIG General Insurance launched a plan for this group, adding to the considerable number of plans already available

Biocon, Juno Pharma ink pact for commercialisation of Liraglutide in Canada

Under the agreement's terms, Biocon will be responsible for obtaining regulatory approvals for Liraglutide and will subsequently manage the manufacturing and distribution of the product within Canada

Natural light may help treat and prevent type 2 diabetes: Research

Exposure to natural light may help treat and prevent type 2 diabetes, according to a small study. The research, presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Germany from October 2-6, carried out a range of metabolic tests on a group of people with type 2 diabetes when they were exposed to natural light and when they were exposed to artificial light and compared the results. "The misalignment of our internal circadian clock with the demands of a 24/7 society is associated with an increased incidence of metabolic diseases, including type 2 diabetes," said Ivo Habets of Maastricht University, the Netherlands, who co-led the research. "Natural daylight is the strongest zeitgeber, or environmental cue, of the circadian clock, but most people are indoors during the day and so under constant artificial lighting," said Habets. The yet-to-be peer-reviewed study involved 13 participants with an average age of 70 years who stayed in research

Implantable device could allow injection-free diabetes management: Study

The study was published in Proceedings of the National Academy of Science

Dr Reddy's Lab launches generic diabetes medication in US market

Dr Reddy's Laboratories on Thursday said it has launched a generic diabetes medication in the US market. The drug major has launched Saxagliptin and Metformin Hydrochloride extended-release tablets in the US market, the Hyderabad-based company said in a statement. The company's product is a therapeutic equivalent generic version of Kombiglyze XR tablets, it added. Dr Reddy's Saxagliptin and Metformin Hydrochloride extended-release tablets are supplied in a strength of 2.5 mg/1000 mg in bottle count of 60 and strengths of 5 mg/500 mg and 5 mg/1000 mg each in bottle counts of 30, the company said.